Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 2019171-69-6
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the use of pegcetacoplan during breastfeeding. Since only a small dose in injected intravitreally into the eye, it is unlikely that a clinically relevant amount would reach the infant in breastmilk. With the systemic administration of pegcetacoplan, the manufacturer recommends that breastfeeding be discontinued during treatment and for 40 days after the last dose. An alternate drug may be preferred, especially while nursing a newborn or preterm infant.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
(Paroxysmal Nocturnal Hemoglobinuria) Eculizumab
Substance Identification
Substance Name
Pegcetacoplan
CAS Registry Number
2019171-69-6
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- Review Novel targeted C3 inhibitor pegcetacoplan for paroxysmal nocturnal hemoglobinuria.[Clin Exp Med. 2023]Review Novel targeted C3 inhibitor pegcetacoplan for paroxysmal nocturnal hemoglobinuria.Xu B. Clin Exp Med. 2023 Jul; 23(3):717-726. Epub 2022 Apr 19.
- Review Avacincaptad Pegol.[Drugs and Lactation Database (...]Review Avacincaptad Pegol.. Drugs and Lactation Database (LactMed®). 2006
- Review Pacritinib.[Drugs and Lactation Database (...]Review Pacritinib.. Drugs and Lactation Database (LactMed®). 2006
- Review Ipilimumab.[Drugs and Lactation Database (...]Review Ipilimumab.. Drugs and Lactation Database (LactMed®). 2006
- Review Safety and efficacy of pegcetacoplan in paroxysmal nocturnal hemoglobinuria.[Ther Adv Hematol. 2022]Review Safety and efficacy of pegcetacoplan in paroxysmal nocturnal hemoglobinuria.Wong RSM. Ther Adv Hematol. 2022; 13:20406207221114673. Epub 2022 Jul 28.
- Pegcetacoplan - Drugs and Lactation Database (LactMed®)Pegcetacoplan - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...